{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-21-000024","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2021-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:21.021377+00:00","generated_at":"2026-06-30T01:18:44.674158+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vertex Q2 product revenues $1.79B (+18% YoY); raises FY 2021 guidance to $7.2-7.4B","bullets":["Product revenues $1.793B, up 18% YoY; TRIKAFTA/KAFTRIO $1.256B led growth.","GAAP net income $67M ($0.26 diluted EPS); non-GAAP net income $811M ($3.11 EPS).","Raised full-year 2021 product revenue guidance to $7.2-7.4B from $6.7-6.9B.","Recorded $900M payment to CRISPR in Q2 as R&D expense, impacting GAAP results.","CTX001 dosed >45 patients; target enrollment in Phase 3 studies expected Q3 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-21-000024","json":"https://secwatch.observer/filing/0000875320-21-000024.json","markdown":"https://secwatch.observer/filing/0000875320-21-000024.md","text":"https://secwatch.observer/filing/0000875320-21-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000024/0000875320-21-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000024/vrtx-20210729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T01:18:44.674158+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}